Dbv technologies announces new england journal of medicine publication of phase 3 epitope trial data evaluating viaskin™ peanut in toddlers

Montrouge, france, may 10, 2023 dbv technologies announces new england journal of medicine publication of phase 3 epitope trial d ata e valuating viaskin™ peanut in toddlers th e new england journal of medicine (nejm) published results that demonstrated epicutaneous immunotherapy (epit tm ) with viaskin peanut was statistically superior to placebo in desensitizing children to peanut by increasing the peanut dose that triggers allergic symptoms . as stated in an accompanying editorial piece, these data are seen as “ very good news ” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years.
DBVT Ratings Summary
DBVT Quant Ranking